Eisai Buys Alzheimer’s Disease Research Data From TorreyPines
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Eisai said Nov. 11 it signed an agreement with California-based TorreyPines Therapeutics to purchase all research data and assets from TorreyPines' research activities on genes associated with late-onset Alzheimer's disease for an undisclosed upfront payment